We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

We recently compiled a list of the 12 Best Big Name Stocks to Invest in Now. In this article, we are going to take a look at ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...

Eli Lilly and Company LLY ... as seen in the chart below. Lilly has an Earnings ESP of -2.08% and a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy ...

If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...

Eli Lilly's Q4 FY24 guidance ... % discount versus 2023 U.S. calendar year list pricing illustrates how pricing reforms could impact the company's products. Inflation Reduction Act Competition ...